Finding, Fighting the Fat that Fuels Cancer
News May 20, 2013
Scientists at UT Southwestern Medical Center have made a key observation regarding how fat cells (also referred to as adipocytes) interact with tumor cells and thereby allow a cancer to thrive in dense breast tissue or fatty livers.
Fat cells near tumors secrete a variety of extracellular factors, some of which boost tumor development and progression, the UT Southwestern researchers report in the November issue of the Journal of Clinical Investigation.
The correlation between obesity and various solid and hematological cancers - along with other diseases like diabetes, osteoarthritis, and cardiovascular disease - has long been known.
The ongoing challenge - and the focus of this latest investigation by Dr. Philipp Scherer, Director of the Touchstone Center for Diabetes Research at UT Southwestern - is to identify which extracellular factors are most important in driving tumor growth and to determine how to target them.
The UTSW research has found that endotrophin is a fat cell-derived extracellular factor that fuels the growth of breast tumors in mice.
Working with the lead author, Dr. Jiyoung Park, assistant instructor of internal medicine, Dr. Scherer showed that blocking endotrophin secreted by the rodent’s fat cells had a remarkable effect on breast cancer tumors: blocking endotrophin with an antibody not only reduced tumor growth, but also prevented the cancer from metastasizing to other parts of the body.
“Not all fat is bad, but endotrophin happens to be more abundant in unhealthy fat tissue,” Dr. Scherer said.
“In the context of tumor growth, fat cell-derived endotrophin stimulates the growth of blood vessels that in turn feed cancer cells and enables the tumor to grow more rapidly.
“As we gain weight, we not only have an increased risk of developing cancer, but we also decrease the chance of successfully fighting the tumor,” Dr. Scherer said.
The researchers said future efforts will explore various pathological settings to establish whether this blocking approach is a viable strategy in the clinic.
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE
Comments | 0 ADD COMMENT
1th International Symposium on Minimal Residual Cancer
May 03 - May 05, 2018